COSCIENS Biopharma Inc. (CSCI)
NASDAQ: CSCI · Real-Time Price · USD
3.820
-0.080 (-2.05%)
At close: Aug 1, 2025, 4:00 PM
3.770
-0.050 (-1.31%)
After-hours: Aug 1, 2025, 7:10 PM EDT

Company Description

COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Colombia, the United Kingdom, and internationally.

It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a chewable for cholesterol reduction; beta glucan from yeast, a nutraceutical-capsule used as an immune booster; and avenanthramides, a nutraceutical-chewable formulation used to reduce inflammation for the healthcare and cosmetic industries.

It also provides Macrilen/Ghryvelin (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as for endocrinology and oncology indications.

The company sells its products through its distribution network. It has license agreements with Pharmanovia, MegaPharm Ltd., ER Kim Pharmaceuticals Bulgaria Eood, and NK MEDITECH Ltd, as well as Agriculture Canada and University of Alberta.

The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024.

COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.

COSCIENS Biopharma Inc.
COSCIENS Biopharma logo
CountryCanada
Founded1990
IPO DateJul 18, 1996
IndustryBiotechnology
SectorHealthcare
Employees40
CEOAnna Biehn

Contact Details

Address:
222 Bay Street, Suite 3000
Toronto, ON M5K 1E7
Canada
Websitecosciensbio.com

Stock Details

Ticker SymbolCSCI
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001113423
CUSIP Number22112H101
ISIN NumberCA22112H1010
SIC Code2834

Key Executives

NamePosition
Anna Elizabeth BiehnChief Executive Officer
Giuliano La FrattaSenior Vice President of Finance and Chief Financial Officer
Michel Regnier P. Eng.Senior Vice President of Technical operations, MD of Ceapro Inc. and Chief Technology Officer
Dr. Michael Teifel Ph.D.Senior Vice President of GmbH and Chief Scientific Officer
Dr. Matthias GerlachSenior Vice President Manufacturing and Supply Chain and Head of Production

Latest SEC Filings

DateTypeTitle
Jun 30, 20256-KReport of foreign issuer
Jun 11, 2025SCHEDULE 13D/AFiling
Jun 9, 20256-KReport of foreign issuer
Jun 2, 20256-KReport of foreign issuer
May 30, 20256-KReport of foreign issuer
May 27, 20256-KReport of foreign issuer
May 20, 20256-KReport of foreign issuer
May 13, 20256-KReport of foreign issuer
May 13, 20256-KReport of foreign issuer
May 2, 20256-KReport of foreign issuer